Vertex Pharmaceuticals' Product Kalydeco for CF in Young Children
Good news for Vertex (VRTX) product Kalydeco® (ivacaftor) is the first cystic fibrosis (CF) product to be prescribed for children ages six months to less than 12 months. Beneficiary children are those who have at least one mutation in their . . .
This content is for paid subscribers.
Today’s Highlights
May 2, 2019
